Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
40.14
-0.02 (-0.05%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Roche Holding AG Basel American Depositary Shares
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
27
28
Next >
7 Potential Biotech Stocks Buyout Targets in 2022
April 21, 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company.
Via
InvestorPlace
FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis
April 20, 2022
The U.S. FDA is warning that noninvasive prenatal screening (NIPS) tests may provide false results, such as stating a fetus may have a genetic abnormality when the fetus was...
Via
Benzinga
4 Undervalued Biotech Stocks to Add to Your Buy List
April 20, 2022
These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns.
Via
InvestorPlace
Lessons For Elon Musk: 5 Notorious Failed Hostile Takeovers
April 16, 2022
Let’s pause to consider earlier attempts at hostile takeovers by well-respected and well-financed entities and individuals that — to ransack some Musk-worthy clichés — took off like a rocket ship but...
Via
Talk Markets
Why Are ImmunoGen Shares Trading Lower Today
March 21, 2022
ImmunoGen Inc (NASDAQ: IMGN)
Via
Benzinga
Lessons For Elon Musk: 5 Notorious Failed Hostile Takeovers
April 15, 2022
As any student of industry knows, Elon Musk is hardly the first person to attempt a hostile takeover.
Via
Benzinga
FDA Extends Review Period For Regeneron's COVID-19 Antibody Therapy
April 14, 2022
Via
Benzinga
Volume Springs Back Into The OTC Markets In March – Take A Look At Some Of The Top Movers
April 14, 2022
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Trading volume appears to be moving back to OTC Markets...
Via
Benzinga
Read Why Pliant Therapeutics Shares Are Soaring Today
April 13, 2022
Pliant Therapeutics Inc (NASDAQ: PLRX) says that with just two FDA-approved Idiopathic Pulmonary Fibrosis drugs, it believes that is a high unmet need.
Via
Benzinga
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
April 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal
Via
Benzinga
Healthcare Stocks Lead the Way Up as the Market Fades
April 11, 2022
With inflation and energy costs soaring, the Fed ever threatening with higher rates and headlines from the war in Ukraine investors are seeking more defensive positions.
Via
Talk Markets
BioNTech And Matinas BioPharma Announce Exclusive Research Collaboration To Evaluate Novel Delivery Technology For mRNA-based Vaccines
April 11, 2022
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
Recession Fears are Creating a Golden Opportunity for Biotech Stocks
April 08, 2022
Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now.
Via
InvestorPlace
How Medicare 'Snuffed Out' Hope For Biogen's Controversial Alzheimer's Drug
April 08, 2022
Only Medicare patients enrolled in specific studies will receive reimbursement.
Via
Investor's Business Daily
Good and Bad stock news
April 05, 2022
Microsoft is down because of an FTC investigation of its possible anti-competitive moves.
Via
Talk Markets
New Data for Genentech’s Ocrevus (ocrelizumab) Show Benefit in Disability Progression and Cognitive Decline in Both Secondary Progressive and Primary Progressive Multiple Sclerosis
April 04, 2022
From
Genentech
Via
Business Wire
SoftBank Loses Vision Fund Leader; Continues To Liquidate Portfolio
April 04, 2022
Ron Fisher looked to depart as the head of SoftBank Group Corp's (OTC: SFTBY) (OTC: SFTBF) Vision Fund and Chair and director of SoftBank Investment Advisors U.S....
Via
Benzinga
Genentech's Ocrevus Shows Benefit In Disability Progression & Cognitive Decline In Multiple Sclerosis
April 04, 2022
Via
Benzinga
FDA Grants Priority Review To Roche's Actemra For Hospitalized COVID-19 Adults
April 04, 2022
Via
Benzinga
U.S. FDA Grants Priority Review to Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults
April 04, 2022
From
Genentech
Via
Business Wire
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
April 01, 2022
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with...
Via
Benzinga
Roche's Tiragolumab Immunotherapy Flunks In Late-Stage Lung Cancer Trial
March 30, 2022
Roche Holding AG's (OTC: RHHBY) Phase 3 SKYSCRAPER-02 study in extensive-stage small-cell lung cancer (ES-SCLC)
Via
Benzinga
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
March 30, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Genentech Provides Update on Phase III SKYSCRAPER-02 Study in Extensive-Stage Small Cell Lung Cancer
March 30, 2022
From
Genentech
Via
Business Wire
Biotech Funds and ETFs Continue to Lag
March 28, 2022
It’s no secret that market sectors driving inflation are leading the market. With the US economy still strong and the War in Ukraine limiting supply of nat gas and raw materials, producer costs are...
Via
Talk Markets
Drug makers, Scientists Working For Long COVID Treatments: Reuters
March 25, 2022
Researchers and drugmakers, including those who have launched antiviral pills and monoclonal antibodies for COVID-19, are having early discussions about targeting Long COVID,
Via
Benzinga
The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO
March 25, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Flood Helping Ukraine
March 24, 2022
Emerging markets are gaining as mature markets look risky.
Via
Talk Markets
How Rivals Merck, Bristol Myers Benefit From Eli Lilly's FDA Snag
March 24, 2022
The Food and Drug Administration on Thursday rejected a lung cancer drug Eli Lilly tested only in China, but LLY stock inched higher.
Via
Investor's Business Daily
Up On Bad News
March 22, 2022
Despite the plane crash in China, Boeing's stock is up today.
Via
Talk Markets
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
27
28
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.